NeoGenesis Capital launches debut fund targeting Colossal Biosciences spinouts
Monday, October 19, 2026 · first reported by AltAssets
NeoGenesis Capital launched its debut venture capital fund targeting spinout businesses from Colossal Biosciences' genetic engineering platform.
- Also named
- Colossal Biosciences
- Stage
- Launch
- Asset class
- Venture
- Geography
- North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 source- Inovia hits $200m in first close for sixth early-stage fundVenture Capital Journal
- OrbiMed Banks $3 Billion for Two Healthcare Venture FundsWSJ +11
- Castello's energy transition fund hits €45M in second closeDealroom
- University-backed funds target Hong Kong’s deep-tech funding gapstartupbusiness.it
- Pear VC raises $333m for smaller fifth fund, promotes three executives to GPAltAssets +1
- New venture capital offers Israel's new immigrants up to $500,000 in fundingThe Jerusalem Post